<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03076164</url>
  </required_header>
  <id_info>
    <org_study_id>15-098</org_study_id>
    <nct_id>NCT03076164</nct_id>
  </id_info>
  <brief_title>A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib</brief_title>
  <official_title>A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability and overall response rate&#xD;
      of trametinib when given in combination with erlotinib in patients with Stage IV or recurrent&#xD;
      lung adenocarcinoma that cannot be treated with curative intent.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">December 18, 2020</completion_date>
  <primary_completion_date type="Actual">December 18, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Trametinib 1.5mg + Erlotinib 75mg</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>2 years</time_frame>
    <description>Response and progression of disease will be evaluated in this study using interval imaging every 8 weeks with CT scan of the chest and imaging of any other target lesion with response evaluated by RECIST 1.1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability will be evaluated by systematic and regular toxicity evaluations. Toxicity will be graded according to NCI CTCAE version 4.0.</measure>
    <time_frame>2 years</time_frame>
    <description>Safety and tolerability will be evaluated by systematic and regular toxicity evaluations. Toxicity will be graded according to NCI CTCAE version 4.0.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Lung Adenocarcinoma</condition>
  <condition>Lung Cancer</condition>
  <condition>Lung Cancer Metastatic</condition>
  <condition>Lung Cancer Stage IV</condition>
  <condition>Recurrent Lung Adenocarcinoma</condition>
  <condition>Recurrent Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Trametinib 1.5mg + Erlotinib 75mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1: Accrue 6 patients on Trametinib 1.5mg + Erlotinib 75mg by mouth once daily Phase 2: Accrue 24 patients (including 6 patients treated during Phase 1) on Trametinib 1.5mg + Erlotinib 75mg by mouth once daily or Trametinib 1.0mg + Erlotinib 100mg by mouth once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <description>Trametinib 1.5mg once daily by mouth</description>
    <arm_group_label>Trametinib 1.5mg + Erlotinib 75mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Erlotinib 75mg once daily by mouth</description>
    <arm_group_label>Trametinib 1.5mg + Erlotinib 75mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologic evidence of advanced stage IV or recurrent lung adenocarcinoma reviewed at&#xD;
             MSKCC&#xD;
&#xD;
          -  Somatic activating mutation in EGFR Radiographic progression during treatment with&#xD;
             erlotinib.&#xD;
&#xD;
          -  Any number of prior chemotherapy regimens is permitted.&#xD;
&#xD;
          -  Measurable (RECIST 1.1) indicator lesion not previously irradiated&#xD;
&#xD;
          -  KPS &gt;/= 70%&#xD;
&#xD;
          -  Age &gt;18 years old&#xD;
&#xD;
          -  Must have undergone biopsy after development of acquired resistance to erlotinib with&#xD;
             available archived tissue (equivalent of &gt; 10 unstained slides)&#xD;
&#xD;
          -  Left ventricular Ejection Fraction &gt;/= the lower limit of normal by ECHO or MUGA&#xD;
&#xD;
          -  Adequate organ function:&#xD;
&#xD;
          -  AST, ALT &lt;/= 2.5 x ULN&#xD;
&#xD;
          -  Total bilirubin &lt;/= 1.5 x ULN&#xD;
&#xD;
          -  Albumin&gt;/=2.6g/dL - Creatinine &lt; 1.5 x ULN OR calculated creatinine clearance&#xD;
             &gt;/=50mL/min&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;/= 1,200 cells/mm3&#xD;
&#xD;
          -  Hemoglobin&gt;/=9.0 g/dL&#xD;
&#xD;
          -  Platelets &gt;/=100,000/mm3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with symptomatic brain metastasis requiring escalating doses of steroids&#xD;
&#xD;
          -  Patients with grade 2 or greater diarrhea prior to study initiation despite maximal&#xD;
             medical management due to medications or a medical condition such as Crohn's disease&#xD;
             or malabsorption&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Any type of systemic therapy (chemotherapy or experimental drugs) within 2 weeks of&#xD;
             starting treatment on protocol except for a EGFR TKI&#xD;
&#xD;
          -  Patients who have received prior treatment with a MEK inhibitor&#xD;
&#xD;
          -  Any major surgery or extensive radiotherapy within 21 days of starting treatment on&#xD;
             protocol.&#xD;
&#xD;
          -  A history of clinically significant interstitial lung disease or pneumonitis&#xD;
&#xD;
          -  Clinically significant cardiac disease including unstable angina, acute myocardial&#xD;
             infarction within 6 months from Day 1 of study administration, New York Heart&#xD;
             Association Class III or IV congestive heart failure, or symptomatic uncontrolled&#xD;
             Arrythmias, prolonged corrected QT interval &gt;480msec, treatment refractory&#xD;
             hypertension, presence of a cardiac defibrillator&#xD;
&#xD;
          -  History of central serous retinopathy or retinal vein occlusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helena Yu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Cancer Center</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 6, 2017</study_first_submitted>
  <study_first_submitted_qc>March 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2017</study_first_posted>
  <last_update_submitted>December 21, 2020</last_update_submitted>
  <last_update_submitted_qc>December 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>erlotinib</keyword>
  <keyword>trametinib</keyword>
  <keyword>15-098</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Adenocarcinoma of Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Trametinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>October 14, 2021</submitted>
    <returned>November 11, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

